Renascience Inc. (4889.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 1,153.00

From 52W high−49.47%

Volume170700.00

Market capJPY 14.71B

P/E (TTM)—

P/S (TTM)214.6x

Div yield—

Key dataSep 18, 2026

Open

JPY 1,153.00

From 52W high

−49.47%

Volume

170700.00

Market cap

JPY 14.71B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−34.3x

P/E (TTM)

—

RSI (14)

44.4

MomentumView details →

1D Return

+1.23%

YTD Return

−15.75%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−34.3x

EV/Sales

167.8x

P/S (TTM)

214.6x

P/B (TTM)

4.5x

ProfitabilityView details →

Gross Margin

94.42%

Net Margin

−442.65%

EBITDA Margin

—

ROE (TTM)

−9.06%

ROA (TTM)

−8.59%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−48.48%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−12.06%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+1.23%

YTD Return

−15.75%

1Y Return

−40.76%

RSI (14)

44.4

vs 50D SMA

−11.64%

vs 200D SMA

−22.96%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

19.40x

Quick Ratio

19.40x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

68.00M

Net Income (TTM)

−301.00M

Op. CF (TTM)

—

Next earningsNov 5, 2026 →

Latest newsMore news →

Renascience Inc. has initiated a Phase 2 clinical trial of its PAI-1 inhibitor RS5614 for locally advanced non-small cell lung cancer.61d ago

Renascience announced the start of a Phase II physician-led trial of PAI-1 inhibitor RS5614 in combination with chemoradiotherapy and durvalumab for locally advanced non-small cell lung cancer, with first patient dosed on July 16, 2026.61d ago

Similar companies

STELLA PHARMA CORPORATION4888.T CanBas Co.,Ltd.4575.T RaQualia Pharma Inc.4579.T TAIKO PHARMACEUTICAL CO.,LTD.4574.T AnGes,Inc.4563.T MediciNova,Inc.4875.T Find similar companies →

Latest newsMore news →

Renascience Inc. has initiated a Phase 2 clinical trial of its PAI-1 inhibitor RS5614 for locally advanced non-small cell lung cancer.61d ago Renascience announced the start of a Phase II physician-led trial of PAI-1 inhibitor RS5614 in combination with chemoradiotherapy and durvalumab for locally advanced non-small cell lung cancer, with first patient dosed on July 16, 2026.61d ago